| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update | 206 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m.... ► Artikel lesen | |
| 15.04. | Innate Pharma SA: Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 | 172 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024... ► Artikel lesen | |
| 15.04. | Innate Pharma SA: Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients | 397 | Business Wire | Partner Sanofi advances SAR443579 IPH6101, ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager, to Phase 2 dose expansion in blood cancers Dosing of the first... ► Artikel lesen | |
| 10.04. | Innate Pharma plans IND of ADC candidate after positive preclinical data | 3 | Pharmaceutical Technology | ||
| 10.04. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 10.04. | Innate Pharma SA: Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate | 211 | Business Wire | IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting... ► Artikel lesen | |
| 09.04. | Innate Pharma SA: Innate Pharma Announces Its Participation in Upcoming Investor Conference | 269 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming... ► Artikel lesen | |
| 05.04. | Innate Pharma SA: Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F | 292 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2023 Universal Registration Document (Document d'enregistrement... ► Artikel lesen | |
| 04.04. | Innate Pharma SA - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 22.03. | Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript | 2 | Insider Monkey | ||
| 22.03. | Earnings call: Innate Pharma reports on progress and outlook for 2023 | 3 | Investing.com | ||
| 21.03. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.03. | Innate Pharma GAAP EPS of -€0.09, revenue of €61.64M | 1 | Seeking Alpha | ||
| 21.03. | Innate Pharma SA: Innate Pharma Reports Full Year 2023 Financial Results and Business Update | 476 | Business Wire | Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress... ► Artikel lesen | |
| 21.03. | Innate Pharma Reports Full Year 2023 Financial Results and Business Update | 103 | Business Wire | MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the... ► Artikel lesen | |
| 19.03. | Innate Pharma SA: Innate Pharma Announces Its Participation to Upcoming Investor Conference | 371 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming... ► Artikel lesen | |
| 14.03. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 14.03. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results | 254 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2... ► Artikel lesen | |
| 06.03. | Innate Pharma SA - 6-K, Report of foreign issuer | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 1.978 |
| NEL | 1.867 |
| SIEMENS ENERGY | 1.641 |
| TUI | 1.281 |
| MERCEDES-BENZ | 1.279 |
| BAYER | 1.242 |
| PALANTIR TECHNOLOGIES | 1.189 |
| NVIDIA | 925 |
| ALLIANZ | 920 |
| DEUTSCHE BANK | 918 |
| DEUTSCHE LUFTHANSA | 882 |
| BYD | 843 |
| PLUG POWER | 807 |
| BORUSSIA DORTMUND | 775 |
| INFINEON | 741 |
| PUMA | 738 |
| VARTA | 731 |
| SMA SOLAR | 687 |
| FRESENIUS | 635 |
| RWE | 631 |
| VOLKSWAGEN | 628 |
| TESLA | 624 |
| RHEINMETALL | 612 |
| AIXTRON SE | 611 |
| SUPER MICRO COMPUTER | 592 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
